中東およびアフリカの炭疽症治療市場レポート - 産業動向と2029年までの予測

中東およびアフリカ炭疽菌治療市場、タイプ別（皮膚炭疽菌、肺炭疽菌、腸炭疽菌）、投与経路別（経口、非経口、その他）、エンドユーザー別（政府機関、病院、学術研究機関、その他）業界動向および2029年までの予測。

中東およびアフリカ炭疽菌治療市場

中東およびアフリカ炭疽菌治療市場の分析と洞察

中東およびアフリカの炭疽菌治療市場は、細菌感染の発生率の上昇、研究資金の増加、炭疽菌治療のための新しい治療法の開発、パイプライン製品による需要の増大、研究開発への投資の増加などの要因によって牽引されており、市場の成長につながっています。現在、先進国および新興国全体で医療費が増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性が生まれると予想されています。

中東およびアフリカ炭疽菌治療市場

炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加は、市場にさらなる影響を与えています。ただし、治療と手順に関連する高コスト、および製品承認に関する厳格な政府規制が、炭疽菌治療市場の成長を妨げると予想されます。

中東およびアフリカ炭疽菌治療市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。

中東およびアフリカの炭疽菌治療市場は支援的であり、病気の進行を抑えることを目指しています。データブリッジマーケットリサーチは、中東およびアフリカの炭疽菌治療市場は2022年から2029年の予測期間中に8.6%のCAGRで成長すると分析しています。

レポートメトリック	詳細
予測期間	2022年から2029年
基準年	2021
歴史的な年	2020 (2019 - 2014 にカスタマイズ可能)
定量単位	売上高は百万米ドル、価格は米ドル
対象セグメント	タイプ別（皮膚炭疽、肺炭疽、腸炭疽）、投与経路別（経口、非経口、その他）、エンドユーザー別（政府機関、病院、学術研究機関、その他）業界動向と2029年までの予測
対象国	サウジアラビア、南アフリカ、UAE、イスラエル、エジプト、その他の中東およびアフリカ
対象となる市場プレーヤー	Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、Lupin、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited など

中東およびアフリカ炭疽菌治療市場の動向

市場の定義

炭疽病は、炭疽菌 (B. anthracis) と呼ばれる細菌によって引き起こされます。これは主に、土壌中の胞子を摂取することで感染する家畜の病気です。人間は通常、皮革や羊毛などの感染した動物の製品を扱ったり、感染した動物製品から炭疽菌の胞子を吸い込んだりすることで炭疽病に感染します。感染した動物の肉を調理が不十分な状態で食べることでも感染することがあります。炭疽病が人から人へ感染することは知られていません。

炭疽菌感染症には 3 つの臨床的形態があります。皮膚炭疽菌感染症が最も一般的で、報告された症例の 95% 以上を占めています。皮膚炭疽菌感染症は、皮膚の擦り傷から胞子が侵入することで発生し、世界中で毎年 2,000 件発生していると推定されています。

炭疽菌の鑑別診断には、臨床的特徴に応じて、血液、胸水、潰瘍部位、脳脊髄液、および便からの PCR 、グラム染色、培養などの関連検体が含まれます。利用可能な技術は多数あります。ほとんどのアッセイは、培養ベースの従来の方法、免疫学的検出、核酸ベースのアッセイ、リガンドベースの検出、およびバイオセンサーのいずれかの技術を使用して、微生物全体、微生物抗原、または微生物核酸を検出することに基づいています。

ドライバー

炭疽菌感染症の蔓延

細菌感染症の発生は世界中で増加しています。炭疽は、好気性グラム陽性胞子形成細菌である炭疽菌によって引き起こされる細菌感染症です。炭疽菌胞子の侵入経路に応じて、主に皮膚、肺、または胃腸の感染症として発生します。後に、特徴的な黒いかさぶた状の斑点が患部の皮膚に現れ、数週間後には緩み始め、最終的に剥がれ落ちて瘢痕を残します。これらの経過は非常に特徴的であるため、まれではありますが、この病気に精通している医師が診断を見逃すことはほとんどありません。肺炭疽は、3 種類の炭疽の中で最も致命的で、吸入された胞子が気管気管支リンパ節内で発芽して増殖します。炭疽は、人間と動物の両方に影響を与える有害な病気です。これは炭疽菌によって引き起こされる生命を脅かす感染症です。炭疽菌感染症の発生率と蔓延が増加しているため、少量の感染でも検出できる感度の高い診断アプローチの必要性が高まっています。

炭疽菌に苦しむ人々の数が世界中で増加していることは、炭疽菌治療市場の成長を牽引する主な要因の 1 つです。新しい治療法を開発する研究者への資金援助の増加、および民間人や軍隊における炭疽菌への曝露の脅威の増加が、市場の成長を加速させています。研究開発プログラムの数の増加、および革新的で効果的な治療法の新たな開発を促進するための官民パートナーシップの増加が、市場にさらなる影響を与えています。

炭疽菌治療対象者に対する研究資金の増加と新しい治療法の開発

さまざまなタイプの患者を治療するための手順を変更するには、研究開発が必須条件です。炭疽菌治療の需要は、すべての国を巻き込んで世界中で高まっています。そのため、企業は患者に効果的な治療を提供することに成功するために、研究開発に継続的に注力しています。近年、診断を新たな段階に進める多くの診断アプローチが登場しており、人体中の寄生虫の最小量さえも検出できるものが多くあります。

診断におけるこれらの新しいアプローチは、市場を前進させるでしょう。研究資金の増加と炭疽菌治療のための新しい治療法の開発により、炭疽菌に対して効果的に作用するために細菌の増殖と毒素生成の両方を標的とする、いくつかの新しい抗生物質と既存の抗生物質、および有望性が高まっている毒素阻害剤があります。

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. The new tools developed have the efficiency to detect bacterial infection in fewer intervals of time with higher efficacy rate, which allows consumers to achieve appropriate treatment at correct time. Thus, this signifies that increasing research and development is expected as driver for the Middle East and Africa anthrax treatment market growth

Opportunities

Rising product launch

Human infection is usually via contact with infected animals or animal products and may manifest as a cutaneous, inhalational, or gastrointestinal infection. The worldwide incidence of anthrax is generally increasing. Therefore, the growing patient pool of the disease across the world is demanding highly effective and advanced anthrax treatment products to minimize the risk of death owing to anthrax disease. Moreover, the healthcare systems from developed countries prefer the high advancement with fewer risk factors and advanced anthrax treatment products. Owing to this, major market players are highly focused on product launches.

Thus growing product launches provide highly effective and advanced medical treatment products for a better patient experience. New product launches generate attention for the company as well as create the company's presence in the Middle East and Africa market. The fundamental beneficial factor of the product launch is escalating the company’s business growth. Whereas new product launches create the revenue stream for the company and the revenue stream that establish with the product launch can be persistent for many years. Owing to this, it is estimated that new product launches is expected a tremendous opportunity for the market players to elevate their business growth in the anthrax treatment market.

Restraints/Challenges

High cost of treatment

The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Since diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased. The high cost of the procedure is due to the various checkpoints of the treatments along with the use of high-tech modalities to perform such procedures. As the cost of technological advanced devices is high, the procedure cost proportionally gets escalated, due to which high cost of the procedure is expected to hamper the demand of the market.

Moreover, asymptomatic infections have to go through very specific tests for the identification of bacteria which are costly. Since the high cost of diagnosis for the anthrax, it is expected to restrain the market growth. As the cost of identification treatments is too high, it restricts physicians and patients to accommodate a high-quality and effective solution. Henceforth, the high cost of the treatment procedures has a negative impact on the cost of the overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that high-cost procedures are expected to act as a restraint on the Middle East and Africa anthrax treatment market growth.

Recent Development

In June 2022, Emergent BioSolutions Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 which is a new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age with recommended antibacterial drugs.
In January 2022, Alembic Pharmaceuticals Limited announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg which is used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This results in expansion of product portfolio of the company.

Middle East and Africa Anthrax Treatment Market Segmentation

Middle East and Africa anthrax treatment market is categorized into three notable segments based on type, route of administration and end user. The growth among segments helps you analyses niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

Cutaneous Anthrax
Pulmonary Anthrax
Intestinal Anthrax

On the basis of type, the Middle East and Africa anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax.

Route of Administration

Cutaneous Anthrax
Pulmonary Anthrax
Intestinal Anthrax

On the basis of route of administration, Middle East and Africa anthrax treatment market is segmented into oral, parenteral and others.

End User

Government Organization
Hospitals
Academic and Research Institutes,
Others

炭疽菌治療市場

On the basis of end user, Middle East and Africa anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others.

Anthrax Treatment Market Regional Analysis/Insights

The Middle East and Africa anthrax treatment market is analysed and market size insights and trends are provided by type, route of administration and end user as referenced above.

The countries covered in the anthrax treatment report are Saudi Arabia, South Africa, U.A.E, Israel, Egypt, Rest of Middle East and Africa.

発展途上地域での技術進歩の進展により、南アフリカが優位に立つことが予想されます。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリューチェーン分析、技術動向、ポーターの 5 つの力の分析、ケーススタディなどのデータポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、中東およびアフリカのブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、国内関税と貿易ルートの影響を考慮しながら、国別データの予測分析を提供します。

競争環境と炭疽菌治療市場シェア分析

中東およびアフリカ炭疽菌治療市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、中東およびアフリカでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供された上記のデータポイントは、炭疽菌治療市場に対する会社の重点にのみ関連しています。

この市場のプレーヤーとしては、Alembic Pharmaceuticals、Sun Pharmaceutical Industries Ltd.、Zydus Group、Bayer AG、Pfizer Inc.、Lupin、Teva Pharmaceutical Industries Ltd.、ARISTO Pharmaceuticals Private Limited などがあります。

研究方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレントモデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、企業市場シェア分析、測定基準、中東およびアフリカと地域、ベンダーシェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。

SKU-68921

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020-

TABLE 2 VACCINES IN DEVELOPMENT

TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018-

TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION-

TABLE 5 RECENT M&A IN ANTHRAX MARKET-

TABLE 6 ANTIBIOTICS MEDICINES

TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED

TABLE 8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 48 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 49 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 52 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 53 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 55 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 56 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 58 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 59 MIDDLE EAST AND AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 63 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 64 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 67 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 68 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 70 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 71 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 73 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 74 MIDDLE EAST AND AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 77 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 78 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 79 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 82 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 83 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 85 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 86 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 87 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 88 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP)

TABLE 89 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 91 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 93 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 94 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 96 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 99 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 101 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 102 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 103 SOUTH AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 104 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 107 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 109 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 110 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 111 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 112 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 114 SOUTH AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 118 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 119 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 120 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 121 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 123 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 125 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 126 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 127 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 128 SAUDI ARABIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 132 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 135 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 136 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 137 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 139 SAUDI ARABIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 141 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 142 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 143 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 144 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 146 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 148 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 150 SAUDI ARABIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 151 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 152 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 154 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 155 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 157 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 158 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 159 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 160 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 161 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 162 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 163 U.A.E ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 U.A.E CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 167 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 168 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 170 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 171 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 173 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 174 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 175 U.A.E PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 176 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 179 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 180 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 181 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 182 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 183 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 184 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 186 U.A.E INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 189 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 190 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 191 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 192 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 193 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 194 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 195 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 196 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 197 U.A.E ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 198 U.A.E ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 199 EGYPT ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 200 EGYPT CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 201 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 202 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 203 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 204 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 205 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 206 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 207 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 208 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 209 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 211 EGYPT PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 212 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 213 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 215 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 216 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 217 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 218 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 219 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 220 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 221 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 222 EGYPT INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 223 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 224 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 225 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 226 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 227 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 228 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 229 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 231 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 232 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 233 EGYPT ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 234 EGYPT ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 235 ISRAEL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 236 ISRAEL CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 237 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 238 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 239 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 240 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 241 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 242 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 243 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 244 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 245 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 246 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 247 ISRAEL PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 248 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 249 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 250 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 251 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 252 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 253 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 254 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 255 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 256 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 257 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 258 ISRAEL INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 259 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 260 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 261 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 262 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 263 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 264 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 265 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 266 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 267 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 268 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS)

TABLE 269 ISRAEL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 270 ISRAEL ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 271 REST OF MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)

図表一覧

FIGURE 1 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: SEGMENTATION

FIGURE 11 MIDDLE EAST & AFRICA IS ANTICIPATED TO DOMINATE THE ANTHRAX TREATMENT MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASING INCIDENCE AND PREVALENCE OF ANTHRAX INFECTIONS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET IN THE FORECAST PERIOD

FIGURE 13 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET IN 2022 & 2029

FIGURE 14 MIDDLE EAST & AFRICA DISTRIBUTION OF OUTBREAKS BY COUNTRY AND GEOGRAPHIC LOCATIONS OF ANTHRAX EVENTS-

FIGURE 15 PATHOPHYSIOLOGY OF ANTHRAX-

FIGURE 16 FLOW CHART FOR SUSPECTED ANTHRAX EXPOSURE-

FIGURE 17 GC BIOPHARMA ANTHRAX CANDIDATE GC1109 IS IN PHASE 2 (NCT01624532).

FIGURE 18 BA-ISTAB IS A FUSION OF A B. ANTHRACIS SPECIFIC CWT WITH A POTENT MONOCLONAL ANTIBODY THAT NEUTRALIZE ANTHRAX TOXIN (PA).

FIGURE 19 TWO ROUTES BY WHICH VACCINATION CAN REDUCE INCIDENCE OF AMR-

FIGURE 20 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET

FIGURE 21 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, 2021

FIGURE 22 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, 2022-2029 (USD MILLION)

FIGURE 23 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, CAGR (2022-2029)

FIGURE 24 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : TYPE, LIFELINE CURVE

FIGURE 25 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2021

FIGURE 26 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 27 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 28 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 29 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, 2021

FIGURE 30 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, 2022-2029 (USD MILLION)

FIGURE 31 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, CAGR (2022-2029)

FIGURE 32 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET : BY END USER, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 34 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 35 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 36 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 37 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET: BY TYPE (2022-2029)

FIGURE 38 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: COMPANY SHARE 2021(%)

詳細情報を見る

調査方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダーシェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータスタイルでいくつでも追加できます。当社のアナリストチームは、粗い生の Excel ファイルピボットテーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータセットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

中東およびアフリカ炭疽菌治療市場 - 2029 年までの業界動向と予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

中東およびアフリカ炭疽菌治療市場の分析と洞察

中東およびアフリカ炭疽菌治療市場の動向

Middle East and Africa Anthrax Treatment Market Segmentation

Anthrax Treatment Market Regional Analysis/Insights

競争環境と炭疽菌治療市場シェア分析

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

レポート

市場洞察

サポート

ソリューション

中東およびアフリカ炭疽菌治療市場 - 2029 年までの業界動向と予測

アジャイルなサプライチェーンコンサルティングで関税の課題を回避

中東およびアフリカ炭疽菌治療市場の分析と洞察

中東およびアフリカ炭疽菌治療市場の動向

Middle East and Africa Anthrax Treatment Market Segmentation

Anthrax Treatment Market Regional Analysis/Insights

競争環境と炭疽菌治療市場シェア分析

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

目次

表のリスト

図表一覧

調査方法

カスタマイズ可能

関連ページを閲覧する